Generic Afinitor is launched in US by Par Pharma /Endo.
Endo International plc announced that one of its operating companies, Par Pharmaceutical (Par), has received approval for and launched generic Afinitor (everolimus) 2.5 mg, 5 mg and 7 mg tablets. Product is available for immediate shipping.
"We are pleased to bring the first generic Afinitor to market and provide patients with a lower-cost option," said Domenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics at Endo. "This launch is a testament to Par's expertise in manufacturing technically challenging products while maintaining excellence in quality."
According to IQVIA data, sales for Afinitor 2.5 mg, 5mg and 7mg tablets were approximately $412 million over the last four quarters.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.